Comment on “Efficacy and Safety of Brodalumab, an Anti‑interleukin‑17 Receptor A Monoclonal Antibody, for Palmoplantar Pustulosis: 16‑Week Results of a Randomized Clinical Trial”

[...]the withdrawal rate was high in the brodalumab treatment group in this study [1], with 13 out of 63 patients sufering from discontinuation of the drug before 16 weeks, which may have biased the results of the trial to some extent. [...]a plethora of clinical reports have documented the occurren...

Full description

Saved in:
Bibliographic Details
Published in:American journal of clinical dermatology 2024-11, Vol.25 (6), p.1023-1024
Main Authors: Wang, Lu-Ying, Ding, Yi-Hang, Hou, Xiu-Juan, Li, Chen
Format: Article
Language:English
Subjects:
Alopecia
Baldness
Chen Li
Clinical trials
Conflicts of interest
Cytokines
Dermatology
Infections
Letter to the Editor
Medicine
Medicine & Public Health
Monoclonal antibodies
Pathogenesis
Pharmacology/Toxicology
Pharmacotherapy
Psoriasis
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites cdi_FETCH-LOGICAL-c256t-530791be44ae69b417512ba41f148c4192420243828b336b1ac852a992f518ad3
container_end_page 1024
container_issue 6
container_start_page 1023
container_title American journal of clinical dermatology
container_volume 25
creator Wang, Lu-Ying
Ding, Yi-Hang
Hou, Xiu-Juan
Li, Chen
description [...]the withdrawal rate was high in the brodalumab treatment group in this study [1], with 13 out of 63 patients sufering from discontinuation of the drug before 16 weeks, which may have biased the results of the trial to some extent. [...]a plethora of clinical reports have documented the occurrence of paradoxical cutaneous manifestations after the administration of IL-17 inhibitors. [...]its skin inflammatory response might be more prone to be mediated by cytokines such as IL-4 and IL-13 and have less connection with IL-17 and TNF-α.
doi_str_mv 10.1007/s40257-024-00895-8
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3116677427</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3116677427</sourcerecordid><originalsourceid>FETCH-LOGICAL-c256t-530791be44ae69b417512ba41f148c4192420243828b336b1ac852a992f518ad3</originalsourceid><addsrcrecordid>eNp9kc1u1DAQxyMEoqXwAhyQJS4cGvD4I3G4LavyIRWBShHHyEkc5NaxF9s5LKd9Be7wJjzNPgmzuwUkDsgHezS_-c94_kXxEOhToLR-lgRlsi4pEyWlqpGlulUcA9RNCUqp2_u3LKms4Ki4l9IVpQxPdbc44o2gkkJ1XPxchmkyPpPgyXbz_Wwcba_7NdF-IB_0aPKahJG8iGHQbp50d4oZsvDZbjffrM8mOjNfW48R1OTC9GaVQyQL8jb40LvgtdvTXRjWp2TE1HvtprBy2meNwZzy7EKy6TmBCkU-GXONMml2Oe0aa3KBk4TJfjUDWTrrcTpHLqPVbrv5cb-4M2qXzIOb-6T4-PLscvm6PH_36s1ycV72TFa5lJzWDXRGCG2qphO4FWCdFjCCUL2AhglcjOCKqY7zqgPdK8l007BRgtIDPymeHHRXMXyZTcrtZFNvHP7ChDm1HKCq6lqwGtHH_6BXYY64hh3FBAgugSPFDlQfQ0rRjO0q2knHdQu03XnbHrxtcax2722rsOjRjfTcTWb4U_LbTAT4AUiY8p9N_Nv7P7K_AA0Rs5c</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3124143513</pqid></control><display><type>article</type><title>Comment on “Efficacy and Safety of Brodalumab, an Anti‑interleukin‑17 Receptor A Monoclonal Antibody, for Palmoplantar Pustulosis: 16‑Week Results of a Randomized Clinical Trial”</title><source>Springer Nature</source><source>Alma/SFX Local Collection</source><creator>Wang, Lu-Ying ; Ding, Yi-Hang ; Hou, Xiu-Juan ; Li, Chen</creator><creatorcontrib>Wang, Lu-Ying ; Ding, Yi-Hang ; Hou, Xiu-Juan ; Li, Chen</creatorcontrib><description>[...]the withdrawal rate was high in the brodalumab treatment group in this study [1], with 13 out of 63 patients sufering from discontinuation of the drug before 16 weeks, which may have biased the results of the trial to some extent. [...]a plethora of clinical reports have documented the occurrence of paradoxical cutaneous manifestations after the administration of IL-17 inhibitors. [...]its skin inflammatory response might be more prone to be mediated by cytokines such as IL-4 and IL-13 and have less connection with IL-17 and TNF-α.</description><identifier>ISSN: 1175-0561</identifier><identifier>ISSN: 1179-1888</identifier><identifier>EISSN: 1179-1888</identifier><identifier>DOI: 10.1007/s40257-024-00895-8</identifier><identifier>PMID: 39405016</identifier><language>eng</language><publisher>Cham: Springer International Publishing</publisher><subject>Alopecia ; Baldness ; Chen Li ; Clinical trials ; Conflicts of interest ; Cytokines ; Dermatology ; Infections ; Letter to the Editor ; Medicine ; Medicine &amp; Public Health ; Monoclonal antibodies ; Pathogenesis ; Pharmacology/Toxicology ; Pharmacotherapy ; Psoriasis</subject><ispartof>American journal of clinical dermatology, 2024-11, Vol.25 (6), p.1023-1024</ispartof><rights>The Author(s), under exclusive licence to Springer Nature Switzerland AG 2024</rights><rights>Copyright Springer Nature B.V. Nov 2024</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c256t-530791be44ae69b417512ba41f148c4192420243828b336b1ac852a992f518ad3</cites><orcidid>0009-0007-4700-4657</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,777,781,27905,27906</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39405016$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Wang, Lu-Ying</creatorcontrib><creatorcontrib>Ding, Yi-Hang</creatorcontrib><creatorcontrib>Hou, Xiu-Juan</creatorcontrib><creatorcontrib>Li, Chen</creatorcontrib><title>Comment on “Efficacy and Safety of Brodalumab, an Anti‑interleukin‑17 Receptor A Monoclonal Antibody, for Palmoplantar Pustulosis: 16‑Week Results of a Randomized Clinical Trial”</title><title>American journal of clinical dermatology</title><addtitle>Am J Clin Dermatol</addtitle><addtitle>Am J Clin Dermatol</addtitle><description>[...]the withdrawal rate was high in the brodalumab treatment group in this study [1], with 13 out of 63 patients sufering from discontinuation of the drug before 16 weeks, which may have biased the results of the trial to some extent. [...]a plethora of clinical reports have documented the occurrence of paradoxical cutaneous manifestations after the administration of IL-17 inhibitors. [...]its skin inflammatory response might be more prone to be mediated by cytokines such as IL-4 and IL-13 and have less connection with IL-17 and TNF-α.</description><subject>Alopecia</subject><subject>Baldness</subject><subject>Chen Li</subject><subject>Clinical trials</subject><subject>Conflicts of interest</subject><subject>Cytokines</subject><subject>Dermatology</subject><subject>Infections</subject><subject>Letter to the Editor</subject><subject>Medicine</subject><subject>Medicine &amp; Public Health</subject><subject>Monoclonal antibodies</subject><subject>Pathogenesis</subject><subject>Pharmacology/Toxicology</subject><subject>Pharmacotherapy</subject><subject>Psoriasis</subject><issn>1175-0561</issn><issn>1179-1888</issn><issn>1179-1888</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNp9kc1u1DAQxyMEoqXwAhyQJS4cGvD4I3G4LavyIRWBShHHyEkc5NaxF9s5LKd9Be7wJjzNPgmzuwUkDsgHezS_-c94_kXxEOhToLR-lgRlsi4pEyWlqpGlulUcA9RNCUqp2_u3LKms4Ki4l9IVpQxPdbc44o2gkkJ1XPxchmkyPpPgyXbz_Wwcba_7NdF-IB_0aPKahJG8iGHQbp50d4oZsvDZbjffrM8mOjNfW48R1OTC9GaVQyQL8jb40LvgtdvTXRjWp2TE1HvtprBy2meNwZzy7EKy6TmBCkU-GXONMml2Oe0aa3KBk4TJfjUDWTrrcTpHLqPVbrv5cb-4M2qXzIOb-6T4-PLscvm6PH_36s1ycV72TFa5lJzWDXRGCG2qphO4FWCdFjCCUL2AhglcjOCKqY7zqgPdK8l007BRgtIDPymeHHRXMXyZTcrtZFNvHP7ChDm1HKCq6lqwGtHH_6BXYY64hh3FBAgugSPFDlQfQ0rRjO0q2knHdQu03XnbHrxtcax2722rsOjRjfTcTWb4U_LbTAT4AUiY8p9N_Nv7P7K_AA0Rs5c</recordid><startdate>20241101</startdate><enddate>20241101</enddate><creator>Wang, Lu-Ying</creator><creator>Ding, Yi-Hang</creator><creator>Hou, Xiu-Juan</creator><creator>Li, Chen</creator><general>Springer International Publishing</general><general>Springer Nature B.V</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>4T-</scope><scope>K9.</scope><scope>7X8</scope><orcidid>https://orcid.org/0009-0007-4700-4657</orcidid></search><sort><creationdate>20241101</creationdate><title>Comment on “Efficacy and Safety of Brodalumab, an Anti‑interleukin‑17 Receptor A Monoclonal Antibody, for Palmoplantar Pustulosis: 16‑Week Results of a Randomized Clinical Trial”</title><author>Wang, Lu-Ying ; Ding, Yi-Hang ; Hou, Xiu-Juan ; Li, Chen</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c256t-530791be44ae69b417512ba41f148c4192420243828b336b1ac852a992f518ad3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Alopecia</topic><topic>Baldness</topic><topic>Chen Li</topic><topic>Clinical trials</topic><topic>Conflicts of interest</topic><topic>Cytokines</topic><topic>Dermatology</topic><topic>Infections</topic><topic>Letter to the Editor</topic><topic>Medicine</topic><topic>Medicine &amp; Public Health</topic><topic>Monoclonal antibodies</topic><topic>Pathogenesis</topic><topic>Pharmacology/Toxicology</topic><topic>Pharmacotherapy</topic><topic>Psoriasis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wang, Lu-Ying</creatorcontrib><creatorcontrib>Ding, Yi-Hang</creatorcontrib><creatorcontrib>Hou, Xiu-Juan</creatorcontrib><creatorcontrib>Li, Chen</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Docstoc</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>American journal of clinical dermatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wang, Lu-Ying</au><au>Ding, Yi-Hang</au><au>Hou, Xiu-Juan</au><au>Li, Chen</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Comment on “Efficacy and Safety of Brodalumab, an Anti‑interleukin‑17 Receptor A Monoclonal Antibody, for Palmoplantar Pustulosis: 16‑Week Results of a Randomized Clinical Trial”</atitle><jtitle>American journal of clinical dermatology</jtitle><stitle>Am J Clin Dermatol</stitle><addtitle>Am J Clin Dermatol</addtitle><date>2024-11-01</date><risdate>2024</risdate><volume>25</volume><issue>6</issue><spage>1023</spage><epage>1024</epage><pages>1023-1024</pages><issn>1175-0561</issn><issn>1179-1888</issn><eissn>1179-1888</eissn><abstract>[...]the withdrawal rate was high in the brodalumab treatment group in this study [1], with 13 out of 63 patients sufering from discontinuation of the drug before 16 weeks, which may have biased the results of the trial to some extent. [...]a plethora of clinical reports have documented the occurrence of paradoxical cutaneous manifestations after the administration of IL-17 inhibitors. [...]its skin inflammatory response might be more prone to be mediated by cytokines such as IL-4 and IL-13 and have less connection with IL-17 and TNF-α.</abstract><cop>Cham</cop><pub>Springer International Publishing</pub><pmid>39405016</pmid><doi>10.1007/s40257-024-00895-8</doi><tpages>2</tpages><orcidid>https://orcid.org/0009-0007-4700-4657</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 1175-0561
ispartof American journal of clinical dermatology, 2024-11, Vol.25 (6), p.1023-1024
issn 1175-0561
1179-1888
1179-1888
language eng
recordid cdi_proquest_miscellaneous_3116677427
source Springer Nature; Alma/SFX Local Collection
subjects Alopecia
Baldness
Chen Li
Clinical trials
Conflicts of interest
Cytokines
Dermatology
Infections
Letter to the Editor
Medicine
Medicine & Public Health
Monoclonal antibodies
Pathogenesis
Pharmacology/Toxicology
Pharmacotherapy
Psoriasis
title Comment on “Efficacy and Safety of Brodalumab, an Anti‑interleukin‑17 Receptor A Monoclonal Antibody, for Palmoplantar Pustulosis: 16‑Week Results of a Randomized Clinical Trial”
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-20T05%3A29%3A04IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Comment%20on%20%E2%80%9CEfficacy%20and%20Safety%20of%20Brodalumab,%20an%20Anti%E2%80%91interleukin%E2%80%9117%20Receptor%20A%20Monoclonal%20Antibody,%20for%20Palmoplantar%20Pustulosis:%2016%E2%80%91Week%20Results%20of%20a%20Randomized%20Clinical%20Trial%E2%80%9D&rft.jtitle=American%20journal%20of%20clinical%20dermatology&rft.au=Wang,%20Lu-Ying&rft.date=2024-11-01&rft.volume=25&rft.issue=6&rft.spage=1023&rft.epage=1024&rft.pages=1023-1024&rft.issn=1175-0561&rft.eissn=1179-1888&rft_id=info:doi/10.1007/s40257-024-00895-8&rft_dat=%3Cproquest_cross%3E3116677427%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c256t-530791be44ae69b417512ba41f148c4192420243828b336b1ac852a992f518ad3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=3124143513&rft_id=info:pmid/39405016&rfr_iscdi=true